Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

Aikido Pharma Inc.

Atossa Genetics

Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?

Top Biotech Penny Stocks on Reddit? Check These 3 Out

CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced it has completed enrollment and dosing of all participants in the Company's Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”), utilizing a transcutaneous oxygen monitoring (TCOM) device to evaluate the pharmacodynamic effects of TSC on peripheral tissue oxygenation.

Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study

CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for 2020 and provided a business update.

Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, announced today that Robert J. Cobuzzi, Ph.D., CEO of Diffusion, will present at the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. The presentation will be available on demand during the virtual event for all registered attendees.

Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, announced today the closing of its previously announced underwritten public offering of 29,268,294 shares of its common stock at a price to the public of $1.025 per share, less underwriting discounts and commissions. As previously announced, the Company has granted the underwriter a 30-day option to purchase up to 4,390,244 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock

The stock price of Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) is trading at over 20% pre-market. This is why it happened.

DFFN Stock Price Increases Over 20% Pre-Market: Why It Happened

No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.

Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million

CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 9,756,098 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.

Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021. Conference specifics are as follows:

Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference

Initiated and Advanced C linical Trial Evaluating Lead Product Candidate in COVID-19 Patients

Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates

CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D. to Chief Medical Officer, effective immediately. Dr. Galloway will report to Robert Cobuzzi, Ph.D., Diffusion's Chief Executive Officer.

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

CHARLOTTESVILLE, Va., Sept.  24, 2020  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (N asdaq : DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D., to the position of general counsel and corporate secretary, effective immediately. He will report to Robert Cobuzzi, Ph.D., chief executive officer of Diffusion. As general counsel, Mr. Elder is responsible for overseeing all legal functions, in particular corporate governance, securities and compliance and commercial transactions.

Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary

CHARLOTTESVILLE, Va., Sept.  11, 2020  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Robert Cobuzzi, Ph.D., chief executive officer, will present a corporate overview of the Company on Tuesday, September 15th, at 3:00 p.m. Eastern time.

Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual  Virtual Global Investment Conference

CHARLOTTESVILLE, Va., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who has served as a member of the Company’s Board of Directors since January 2020, will succeed David G. Kalergis as President and Chief Executive Officer effective immediately. Mr. Kalergis will retire from his operational responsibilities but continue to serve as Chairman of the Board.

Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial

Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors

Continues global clinical development of TSC for the treatment of COVID-19 Continues global clinical development of TSC for the treatment of COVID-19

Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

Diffusion Pharmaceuticals (NASDAQ: DFFN) shares are trading lower on Monday after the company received guidance from the FDA on the company's IND for trans sodium crocetinate in Covid-19 patients.

Why Diffusion Pharmaceuticals Is Trading Lower Today

Guidance being incorporated into global study protocol  Enrollment of first patient now expected in August

Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC

Phase 1b dosing expected to begin this month   Data read-out expected later this quarter

Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC

Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected to enroll 224 patients over 12 months, with 24 patients immediately U.S. IND filing planned for later this month Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected to enroll 224 patients over 12 months, with 24 patients immediately U.S. IND filing planned for later this month

Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of TSC in COVID-19 Patients

Share price exceeds $1 at closing for 10 consecutive trading days Share price exceeds $1 at closing for 10 consecutive trading days

Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) shares pushed higher to start the week after the company announced a critical update from the U.S.

Diffusion Pharma’s COVID-19 Treatment Takes a Big Step Forward With the FDA

CHARLOTTESVILLE, Va., May  20, 2020  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body's ability to deliver oxygen to the areas where it is needed most, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with certain institutional and accredited investors of 11,428,572 shares of the Company’s common stock, at a purchase price of $1.05 per share. The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, were approximately $12.0 million.

Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market

Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles

News for Diffusion Pharmaceuticals Stock (DFFN)